Admission to the intensive care unit (ICU) of a patient who has been grafted with hematopoietic stem cells is a serious event, but the role of the ICU in this setting remains controversial. Data were analyzed from patients who underwent autologous or allogeneic bone marrow transplantation at the Centro de Hematología y Medicina Interna de Puebla, México, between May 1993 and October 2014. In total, 339 patients were grafted: 150 autografts and 189 allografts; 68 of the grafted patients (20%) were admitted to the ICU after transplantation: 27% of the allografted and 11% of the autografted patients (p = 0.2). Two of 17 autografted patients (12%) and 5 of 51 allografted patients (10%) survived. All patients who required insertion of an endotracheal tube died, whereas 7 of 11 patients without invasive mechanical ventilation survived (p = 0.001). Only 10% of the grafted patients survived their stay in the ICU; this figure is lower than those reported from other centers and may reflect several facts, varying from the quality of the ICU support to ICU admission criteria to the initial management of all the grafts in an outpatient setting, which could somehow delay the arrival of patients to the hospital.

Keywords:
Allografts, Autografts, Intensive care unit, Mechanical ventilation
1.
Price KJ, Thall PF, Kish SK, Shannon VR, Andersson BS: Prognostic indicators for blood and marrow transplant patients admitted to an intensive care unit. Am J Respir Crit Care Med 1998;158:876-884.
2.
Molina R, Bernal T, Borges M, Zaragoza R, Bonastre J, Granada RM, Rodriguez-Borregán JC, Núñez K, Seijas I, Ayestaran I, Albaiceta GM: Ventilatory support in critically ill hematology patients with respiratory failure. Crit Care 2012;16:R133.
3.
Diaz-de-Heredia C, Moreno A, Olivé T, Iglesias J, Ortega JJ: Role of the intensive care unit in children undergoing bone marrow transplantation with life-threatening complications. Bone Marrow Transplant 1999;24:163-168.
4.
Jackson SR, Tweeddale MG, Barnett MJ, Spinelli JJ, Sutherland HJ, Reece DE, Klingemann HG, Nantel SH, Fung HC, Toze CL, Phillips GL, Shepherd JD: Admission of bone marrow transplant recipients to the intensive care unit: outcome, survival and prognostic factors. Bone Marrow Transplant 1998;21:697-704.
5.
Scales DC, Thiruchelvam D, Kiss A, Sibbald WJ, Redelmeier DA: Intensive care outcomes in bone marrow transplant recipients: a population-based cohort analysis. Crit Care 2008;12:R77.
6.
Ruiz-Delgado GJ, Ruiz-Argüelles GJ: A Mexican way to cope with stem cell transplantation. Hematology 2012;17(suppl 1):195-197.
7.
Kessinger A, Armitage JO, Landmark JD, Smith DM, Weisenburger DD: Autologous peripheral hematopoietic stem cell transplantation restores hemopoietic function following marrow ablative therapy. Blood 1988;71:723-727.
8.
Rivadeneyra-Espinoza L, Pérez-Romano B, González-Flores A, Guzmán-García MO, Carvajal-Armora F, Ruiz-Argüelles A: Instrument and protocol-dependent variation in the enumeration of CD34+ cells by flow cytometry. Transfusion 2006;46:530-536.
9.
López-Otero A, Ruiz-Delgado GJ, Ruiz-Argüelles GJ: A simplified method for stem cell autografting in multiple myeloma: a single institution experience. Bone Marrow Transplant 2009;44:715-719.
10.
Gómez-Almaguer D, Ruiz-Argüelles GJ, Ruiz-Argüelles A, González-Llano O, Cantú OE, Hernández NE: Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis. Bone Marrow Transplant 2000;25:131-133.
11.
Gómez-Almaguer D, Ruiz-Argüelles GJ, Ruiz-Argüelles A, González-Llano O, Cantú OE, Hernández NE: Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis. Bone Marrow Transplant 2000;25:131-133.
12.
Afessa B, Tefferi A, Hoagland HC, Letendre L, Peters SG: Outcome of recipients of bone marrow transplants who require intensive care unit support. Mayo Clin Proc 1992;67:117-122.
13.
Pene F, Aubron C, Azoulay E, Blot F, Thiery G, Raynard B, Schlemmer B, Nitenberg G, Buzyn A, Arnaud P, Societe G, Mira JP: Outcome of critically ill allogeneic hematopoietic stem-cell transplantation recipients: a reappraisal of indications for organ failure supports. J Clin Oncol 2006;24:643-649.
14.
Huaringa AJ, Leyva FJ, Giralt SA, Blanco J, Signes-Costa J, Velarde H, Champlin RE: Outcome of bone marrow transplantation patients requiring mechanical ventilation. Crit Care Med 2000;28:1014-1017.
15.
Depuydt P, Kerre T, Noens L, Nollet J, Offner F, Decruyenaere J, Benoit D: Outcome in critically ill patients with allogeneic BM of peripheral haematopoietic SCT: a single centre experience. Bone Marrow Transplant 2011;46:1186-1191.
16.
Jacobe SJ, Hassan A, Veys P, Mok Q: Outcome of children requiring admission to an intensive care unit after bone marrow transplantation. Crit Care Med 2003;31;1299-1305.
17.
Paz HL, Crilley P, Weinar M, Brodsky I: Outcome of patients requiring medical ICU admission following bone marrow transplantation. Chest 1993;104:527-531.
18.
Cantú-Rodríguez OG, Gutiérrez-Aguirre CH, González-Llano O, Mancías-Guerra C, Jaime-Pérez JC, Tarín-Arzaga LC, Ruiz-Delgado GJ, Sandoval-Villa CC, Marfil-Rivera J, Morales-Toquero A, Ruiz-Argüelles GJ, Gómez-Almaguer D: Outpatient allografting using non-myeloablative conditioning: the Mexican experience. Bone Marrow Transplant 2007;40:119-123.
19.
Cantú-Rodriguez OG, Jaime-Pérez JC, Gutiérrez-Aguirre CH, Treviño-Montemayor OR, Martínez-Cabriales SA, Gómez-Peña A, López-Otero A, Ruiz-Delgado GJ, González-Llano O, Mancías-Guerra MC, Tarín-Arzaga LC, Rodríguez-Romo LN, Ruiz-Argüelles GJ, Gómez-Almaguer D: Low incidence and severity of graft-versus-host disease after outpatient allogeneic peripheral blood stem cell transplantation employing a reduced-intensity conditioning. Eur J Haematol 2011;87:521-530.
20.
Ruiz-Argüelles GJ, Gómez-Almaguer D: Nephrotic syndrome after non-myeloablative stem cell transplantation. Br J Haematol 2006;132:801-802.
21.
Ruiz-Argüelles GJ, Gómez-Almaguer D, López-Martínez B, Ponce-De-León S, Cantú-Rodriguez OG, Jaime-Pérez JC: No cytomegalovirus-related deaths after non-ablative stem cell allografts. Hematology 2002;7:95-99.
22.
Ruiz-Argüelles GJ, Gómez-Rangel JD, Ponce-de-León S, González-Déctor L, Reyes-Núñez V, Garcés-Eisele J: The Mexican schedule to conduct allogeneic stem cell transplantation is related to a low risk of cytomegalovirus reactivation and disease. Am J Hematol 2004;75:200-204.
23.
Ruiz-Argüelles GJ, Gómez-Almaguer D, Steensma DP: Outdated dogma? Busulfan, seizure prophylaxis and stem cell allografting. Am J Hematol 2012;87:941.
24.
Zamora-Ortiz G, Velázquez-Sánchez-de-Cima S, Ponce-de-León S, Gutiérrez-Aguirre CH, Ruiz-Delgado GJ, Gómez-Almaguer D, Ruiz-Argüelles GJ: Secondary malignancies after allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning and outpatient conduction. Hematology 2014;19;435-440.
25.
Escobar K, Rojas P, Ernst D, Bertin P, Nervi B, Jara V, García MJ, Ocqueteau M, Sarmiento M, Ramírez P: Admission of hematopoietic cell transplantation patients to the intensive care unit at the Pontificia Universidad Católica de Chile Hospital. Biol Bone Marrow Transplant 2015;21:176-179.
26.
Eckrich M, Pasquini M: Hematopoietic cell transplantation in Latin America. Hematology 2012;17(suppl 1):S189-S191.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.